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Supplementary information on quality assurance process   11 
  12 
All treating hospitals had to be approved as head and neck treatment centers by their country’s health authorities. All centres and oncologists completed 13 
the trial’s central radiotherapy quality assurance accreditation. All oncologists, surgeons, radiologists and pathologists participating in the study had to be 14 
core members of the approved multi-disciplinary team, fulfilling minimum national qualifications, case throughput and quality assurance criteria. 15 
  16 
  17 
Radiotherapy quality assurance 18 
Randomization was stratified by center to ensure that equal numbers of patients treated and planned by each oncologist and using the same 19 
radiotherapy regimens were randomized to the two treatment arms.  20 
  21 
Centers had to receive radiotherapy trial quality assurance (RTTQA)  credentialing for intensity-modulated radiotherapy (IMRT) in order to enter patients 22 
into the De-ESCALaTE trial. An overview of the complete credentialing process, along with the associated data and documentation, is given on the 23 
National RTTQA group website (www.rttrialsqa.org.uk).The IMRT credentialing programme consisted of five modules: 24 
1)    Outlining benchmark cases: Quality assurance of the performance of clinicians in the outlining process was assessed by sending CT scans of test patients to 25 
each center participating in the study for outlining. Adherence to the trial protocol for the outlining was assessed and analysed by an independent expert 26 
member of the central RTTQA team. 27 
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2)   Planning benchmark cases: Quality assurance of the planning technique was monitored by sending a pre-outlined test patient to each center for planning. 28 
Adherence to the protocol and plan quality was assessed and analysed by an independent expert member of the central RTTQA team. 29 
3)   Processes document: was submitted by the center detailing all aspects of the tasks required for a complete IMRT pathway. 30 
4)   A baseline questionnaire and a trial-specific questionnaire containing questions on a range of aspects relevant to the trial were completed by the center. 31 
5)    Dosimetry audit site visit: consisted of an output measurement and dosimetric measurements of a treatment plan. Audits were carried out either by the 32 
RTTQA group in person.  33 
  34 
Some of the processes were common to other H&N trials running in the UK and, therefore, centers that had previously been credentialed for other trials were 35 
streamlined. 36 
  37 
Changes in technique 38 
If centers changed their outlining or planning technique during the course of the trial, they were required to repeat the QA where appropriate.  39 
  40 
Prospective Case Reviews  41 
The outlining and treatment plans for the first three clinical cases entered into the trial (at least one lateralised and one non-lateralised) from each center had 42 
to be reviewed and approved by the central RTTQA team before treatment could commence. 43 
Trial Data Collection  44 
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Data were collected by the quality assurance team for all patients treated in the De-ESCALaTE trial. This included: CT images, MRI scans (when applicable), 45 
contours, plan and plan dose cubes along with completed plan assessment forms and dose-volume histograms (DVHs). Data were appropriately anonymised. 46 
 47 
Histopathological Quality Assurance 48 
  49 
Quality assurance review of diagnostic samples was undertaken by the central pathology review team at Cellular Pathology, Royal Victoria Infirmary, 50 
Newcastle upon Tyne . p16 immunohistochemistry and high-risk HPV DNA in situ hybridization testing was undertaken for the UK and Ireland by the central 51 
laboratory - Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne, which is an NHS accredited clinical pathology laboratory. For the Netherlands, 52 
testing took place at the VU University Medical Center, Amsterdam.  Neck dissection specimens were reported according to the standards and datasets for 53 
histopathology reporting of nodal excisions and neck dissection specimens associated with head and neck carcinoma.  54 
 55 
Data quality monitoring  56 
On receipt, all forms were checked for completeness and congruity. Forms containing empty data fields or data anomalies were queried with the site for 57 
resolution. Data was entered onto the trial database and any further anomalies were identified and queried with the site. Periodically, data underwent 58 
additional checks to ensure consistency between data submitted on CRFs.  59 
Trial staff maintained regular communication with sites, through routine calls, mailings and/or meetings. In the event of persistent issues with the quality 60 
and/or quality of data submitted, an on-site monitoring visit was arranged. In such circumstances, patient notes and the investigator site files were reviewed 61 
during the visit. The representative from the De-ESCALaTE HPV Trial Office worked with the site staff to resolve issues, offered appropriate training if 62 
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necessary, and determined the site’s future participation in the trial.  63 
An audit were arranged at a site if the Trial Management Group assessed that it is necessary. Audits were conducted by an independent team, determined by 64 
the Trial Management Group.  65 
 66 
 67 
  68 
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Supplementary information on statistical analysis 69 
Monitoring 70 
The IDSMC committee met in accordance with the De_ESCALaTE IDSMC charter. Their main objective was to advise the Trial Steering Committee as to 71 
whether there is evidence or reason why the trial should be amended or terminated based on recruitment rates, compliance, safety or efficacy. The IDSMC 72 
met after the first 50 patients have completed treatment and regularly thereafter. Confidential reports containing recruitment, protocol compliance, safety 73 
data and interim analyses of outcomes will be reviewed by the IDSMC.  74 
Interim analyses of the primary outcome was presented to the IDSMC using conservative tests with significance determine by a p-value of 0.001 (to preserve 75 
the overall alpha level of 0.05). The first interim analysis was done when 200 patients have been recruited (i.e. at least 80 patients have completed treatment 76 
and reached 2 year follow-up). At this time the interim analyses of the secondary endpoints of acute and late toxicity werepresented as well as locoregional 77 
recurrence and overall survival.  78 
 79 
Sample size assumptions: 80 
Calais et al (1999) and Denis et al (2004) are the only studies to report early and late toxicity respectively on (the same cohort of) only oropharyngeal cancer 81 
patients receiving CRT. They report 202 acute severe grade 3-5 toxicities in 108 patients receiving CRT in the acute phase, and 18 late severe toxicities in 27 82 
living patients. They also report that 56% of patients had a severe late toxicity (maximum grade method).  83 
The sample size calculation assumes an average rate of 0.66 late severe toxicity events per patient, as per Denis et al (2004), and an acute toxicity event rate 84 
of 1.85 events per patient (Calais, 1999). Together these would constitute an average of 2.5 severe events per patient.  85 
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Recruiting 304 patients (152 in each arm) will allow reductions greater than 25% in overall number of severe (grade 3-5), acute and late toxicities to be 86 
detected with a 2-sided test at the 5% level of significance allowing for 10% drop out with greater than 90% power. If the event rate is lower than the 87 
estimated 2.5, this sample size also allows the detection of greater than 25% reductions in the overall severe toxicity events at an average rate of up to 1.9 88 
events per patient with 85% power and 1.7 events per patient with 80% power.  89 
Recruiting 304 patients also allows the detection of a 50% reduction in late severe toxicities with at least 90% power and a 25% or more reduction in acute 90 
severe toxicities with 85% power. The calculations were based on simulations and analysis by a Poisson model.  91 
Grade 3/4/5 toxicity events per patient  
 
Power (25% reduction)  
  
Power (33% reduction)  
Power (50% reduction)  
0.5  
 
32%  
  
55%  
94%  
1.0  
 
59%  
  
84%  
99%  
  
1.5  77%  95%  99%  
2.0  
 
88%  
  
99%  
99%  
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2.5  93%  99%  99%  
3.0  
  
97%  
    
99%  
99%  
 92 
The IDSMC on 12th December 2013 recommended that a Poisson distribution should not be assumed for the numbers of toxic events. The assumption of non-93 
Poisson data and use of the Mann-Whitney U test may result in slightly lower or higher power, depending on the distribution.  94 
Early data from the trial suggested that the number of acute serious toxic events per participant may be higher than the pre-trial estimate, e.g. >3 instead of 95 
1.85. Simulations using control arm data similar to this suggested that the power will exceed that in the above text for all comparisons that include acute 96 
events.  97 
Power estimates were revised on the basis of data accrued in June 2016. An increase of 10% in the number of patients randomised to 334 will allow the 98 
detection of a 25% reduction in all severe toxicities with 83% power and a 50% reduction in late severe toxicities with 77% power.  99 
 100 
 101 
 102 
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Definitions of toxicity 103 
Severe toxic event: defined as a toxicity assessed as grade 3-5 by CTCAE V4.0. The type of event was characterised by the CTCAE V4.0 System Organ Class and 104 
Term.  105 
Acute toxic event: defined as occurring during treatment or less than 90 days after the end of treatment.  106 
Late toxic event: defined as occurring between 90 days and two years after end of treatment.  107 
Details of counting events within a period of interest  108 
Multiple occurrences of events of a single toxicity type within an analysis time period are counted as a single event.  Events that were present both in before 109 
90 days after treatment and remained after that period  were counted as acute events and also as late events, but were not double-counted when analysing 110 
the overall number of acute and late events.  111 
 Toxicities reported as part of a serious adverse event notification but that were not reported as toxicity event were added to the counts of toxicity events.  112 
The numbers of patients affected by each of these toxicity categories were reported and compared.  113 
For TAME analysis, the counts were categorised by system organ class, so as to be as close as possible to the Trotti et al method1:  114 
1. The mean number of serious acute events per patient for each of the treatment regimens during the defined acute risk interval were calculated. (This is the 115 
T of TAME in Trotti, 20071).   116 
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2. The mean number of serious late events per patient for each of the treatment regimens during the defined late risk interval were calculated. (This is the A 117 
of TAME).   118 
3. The cumulative incidence of death due to toxicity from study entry up to 30 days after the completion of cancer treatment were calculated (M).   119 
4.E=End results, i.e. the other outcomes.   120 
 Statistical analyses were performed using SAS V9.3 software. 121 
 122 
Quality of life questionnaires 123 
Quality of life aspects have not been specifically measured in HPV+ oropharyngeal patients to date. Indeed, there are very limited quality of life 124 
data specifically for oropharyngeal cancer patients, as most studies have reported on patients with a heterogeneous group of head and neck cancers. 125 
Therefore, there is no pilot data to base power calculations on. This trial allowed this to be quantified. We have followed the EORTC 126 
recommendations for reporting and comparing QoL results using EORTC quality of life questionnaires 127 
(http://groups.eortc.be/qol/downloads/200203guidelines_qol.pdf). The main outcomes of principal interest were overall QoL and swallowing, 128 
however we also reported the other domains. We have reported the mean (and standard deviation) of the overall and domain-specific scores for 129 
both treatment arm groups at each time point (baseline, 3 months, 6 months, 12 and 24 months).  130 
  131 
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Supplementary tables and figures 132 
 133 
Supplementary table S1A: Completion rates of patient reported outcome questionnaires at each time point. 134 
 135 
Timepoint 
  
Cisplatin+RT Cetuximab+RT Total 
Proportion (%) Proportion (%) Proportion (%) 
EORTC QLQ-C30 
Baseline 155/162 (95.7%) 153/165 (92.7%) 308/327 (94.2%) 
End of 
Treatment 124/162 (76.5%) 136/165 (82.4%) 260/327 (79.5%) 
3 months 131/162 (80.9%) 130/165 (78.8%) 261/327 (79.8%) 
6 months 129/162 (79.6%) 127/165 (77%) 256/327 (78.3%) 
12 months 129/162 (79.6%) 128/165 (77.6%) 257/327 (78.6%) 
24 months 97/162 (59.9%) 93/165 (56.4%) 190/327 (58.1%) 
MDADI 
Baseline 155/162 (95.7%) 153/165 (92.7%) 308/327 (94.2%) 
End of 
Treatment 124/162 (76.5%) 136/165 (82.4%) 260/327 (79.5%) 
3 months 131/162 (80.9%) 130/165 (78.8%) 261/327 (79.8%) 
6 months 129/162 (79.6%) 127/165 (77%) 256/327 (78.3%) 
12 months 129/162 (79.6%) 129/165 (78.2%) 258/327 (78.9%) 
24 months 101/162 (62.3%) 96/165 (58.2%) 197/327 (60.2%) 
  136 
 137 
 138 
  139 
  
 
16 
Supplementary table S1B: Co-morbidities of participants. 140 
 141 
 142 
Comorbidity 
(Multiple comorbidities per patient are counted) 
Cisplatin 
(N=163) 
# (%) 
Cetuximab 
(N=165) 
# (%) 
Total* 
(N=338) 
# (%) 
Angina 1 (0.6) 1 (0.6) 2 (0.6) 
Chronic pulmonary disease 1 (0.6) 5 (3.0) 6 (1.8) 
Congestive cardiac failure 1 (0.6) - 1 (0.3) 
Diabetes 17 (10.4) 10 (6.1) 27 (8.2) 
Hypertension 45 (27.6) 36 (21.8) 81 (24.7) 
MI 1 (0.6) 2 (1.2) 3 (0.9) 
Stroke/TIA 1 (0.6) 5 (3.0) 6 (1.8) 
 
Other reported comorbidities grouped 
Asthma 8 4 12 
Blood and lymphatic system disorders - 1 1 
Cardiac disorders 3 4 7 
Ear and labyrinth disorders 1 - 1 
Endocrine disorders 2 3 5 
Eye disorders 1 1 2 
Gastrointestinal disorders 3 7 10 
Hepatobiliary disorders 1 1 2 
Immune system disorders 1 2 3 
Investigations (e.g. hypercholesterol, anaemia) 7 6 13 
Metabolic and nutritional disorders 1 - 1 
Musculoskeletal and connective tissue disorders 6 8 14 
Neoplasms benign, malignant and unspecified 1 2 3 
Nervous system 2 4 6 
Psychiatric 3 8 11 
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Renal and urinary disorders 1 2 3 
Reproductive system and breast disorders 2 2 4 
Respiratory, thoracic and mediastinal disorders 1 1 2 
Skin and subcutaneous tissue disorders - 4 4 
Vascular disorders 1 5 6 
Other/Unclassifiable 6 13 19 
 
Total 118 137 254 
Overall number of comorbidities reported per 
patient 
0.72 0.83 0.77 
 143 
 144 
                                                            *= data not available on some patients  145 
 146 
 147 
 148 
  149 
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Supplementary table S1C: Baseline scores of Patient reported outcomes 150 
 151 
 152 
  Treatment group 
Arm A Arm B 
N Mean SD N Mean SD 
QLQ C30 scores (general QoL) (Scale 0-100, high values are good) 
EORTC QLQ-C30 Global health status 153 77.2 17.2 150 76.6 18.3 
EORTC QLQ-C30 Physical functioning 152 94.6 10.7 151 94.4 9.8 
EORTC QLQ-C30 Role functioning 150 84.1 24.6 150 85.4 24.8 
EORTC QLQ-C30 Emotional functioning 153 79.9 19.3 150 79.0 19.4 
EORTC QLQ-C30 Cognitive functioning 153 90.7 15.3 149 89.4 18.0 
EORTC QLQ-C30 Social functioning 153 83.0 23.4 149 82.8 20.9 
QLQ C30 Symptoms and side effects (Scale 0-100, low values are good) 
EORTC QLQ-C30 Fatigue 152 19.7 21.8 151 17.6 17.9 
EORTC QLQ-C30 Nausea and vomiting 152 3.6 10.7 150 2.9 7.4 
EORTC QLQ-C30 Overall pain 151 19.5 24.8 149 19.6 20.8 
EORTC QLQ-C30 Dyspnoea 152 5.5 13.0 151 5.5 14.1 
EORTC QLQ-C30 Insomnia 151 32.0 27.2 150 28.9 30.1 
EORTC QLQ-C30 Appetite loss 152 13.4 22.5 151 16.3 25.8 
EORTC QLQ-C30 Constipation 152 8.3 17.7 151 12.1 22.3 
EORTC QLQ-C30 Diarrhoea 153 5.2 14.4 150 4.7 13.9 
EORTC QLQ-C30 Financial difficulties 153 19.4 29.5 150 20.0 30.4 
HN35 scores (Head & neck QoL) (Scale 0-100, high values are good) 
EORTC HN35 Pain in head and neck 153 76.1 26.1 151 74.5 22.7 
EORTC HN35 Problems with swallowing 153 90.5 18.1 151 90.9 16.1 
EORTC HN35 Problems with smell/taste 152 94.5 13.5 151 93.4 14.7 
EORTC HN35 Problems with speech 153 91.1 16.8 152 91.7 12.8 
EORTC HN35 Trouble with social eating 153 88.1 22.1 152 88.2 20.8 
EORTC HN35 Trouble with social contact 153 95.5 12.7 152 96.0 9.0 
EORTC HN35 Less sexuality 140 80.0 28.6 142 82.9 26.9 
EORTC HN35 Problems with teeth 153 86.7 27.4 151 83.0 28.8 
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EORTC HN35 Problems opening mouth wide 153 90.0 22.3 151 88.1 24.1 
EORTC HN35 Dry mouth 153 83.4 27.6 151 84.5 24.6 
EORTC HN35 Sticky saliva 153 89.3 21.5 151 90.3 17.5 
EORTC HN35 Coughing 153 83.9 22.0 151 83.4 20.3 
EORTC HN35 Felt ill 153 87.6 22.6 150 88.4 19.3 
EORTC HN35 Used pain killers 152 41.4 49.4 152 31.6 46.6 
EORTC HN35 Used nutritional supplements 153 82.4 38.2 152 83.6 37.2 
EORTC HN35 Used a feeding tube 151 96.0 19.6 152 98.7 11.4 
EORTC HN35 Weight loss - lower score means lost wt 153 71.2 45.4 152 75.7 43.1 
EORTC HN35 Weight gain - lower score means gained wt 152 82.9 37.8 152 83.6 37.2 
MDADI (Dysphagia scale) (Scale 0-100, high values are good) 
MDADI dysphagia global 145 81.0 28.0 145 85.5 23.7 
MDADI dysphagia emotional 149 79.8 18.3 148 83.7 15.1 
MDADI dysphagia functional 149 82.9 18.9 148 84.7 16.1 
MDADI dysphagia physical 149 80.9 23.9 147 83.7 21.0 
MDADI dysphagia composite (overall function) 149 81.1 19.8 148 83.9 16.3 
 153 
 154 
 155 
  156 
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 157 
Supplementary table S2: Numbers of cisplatin doses, and alternative carboplatin doses, received by patients 158 
 159 
 160 
 161 
Number of cycles of 
cisplatin 
Number of doses of carboplatin Total 
Received by each patient No doses 1 dose 2 doses   
0 1 (0.7%) - - 
1 (0.6%) 
 
1 7 (4.7%) 4 (50%) 5 (100%) 16 (9.9%) 
2 79 (53%) 4 (50%) - 83 (51.2%) 
3 62 (41.6%) - - 62 (38.3%) 
Total 149 8 5 
162 
 
 162 
 163 
                                                                 *  4 patients withdrawn before receiving treatment 164 
 165 
 166 
 167 
  168 
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Supplementary table S3: Numbers of cetuximab doses received by patients 169 
 170 
 171 
 172 
 173 
 174 
                                                                        175 
 176 
 177 
 178 
 179 
 180 
 181 
 182 
 183 
*4 patients were withdrawn before receiving treatment 184 
 185 
 186 
 187 
  188 
  189 
Number of doses received Number of participants (%) 
8 130 (79.4%) 
7 23 (13.9%) 
6 0 (0%) 
5 3 (1.8%) 
4 2 (1.2%) 
3 3 (1.8%) 
2 3 (1.8%) 
Total 164 (100%)* 
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 190 
Supplementary table S4: Dose of radiotherapy (Gy) delivered, by arm 191 
 192 
Amount (x) 
Cisplatin+RT 
N (%) 
Cetuximab+RT 
N (%) 
Total 
N (%) 
P-value 
65<x<70 8 (4.9%) 4 (2.5%) 12 (3.7%) 0.256* 
70 145 (89.5%) 152 (92.7%) 297 0.314 
70<x<75 8 (4.9%) 8 (4.9%) 16 0.980 
>75 1 (0.6%) 0 (0%) 1 0.497* 
Total 162 164 326   
*p-value calculated using Fishers exact test, remainder by chi squared 
test 
  193 
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 194 
Supplementary table S5A: Proportion of patients affected by severe and all grade acute, late and overall (combined) toxicities, by treatment group 195 
 196 
Toxicity grouping 
Proportion of patients affected by one or more toxicity events  
Cisplatin+RT Cetuximab+RT 
Acute period      
Grade 3/4/5 142/162 (87.6%) 145/165 (87.9%) 
All grades  162/162 (100%) 165/165 (100%) 
      
Late period     
Grade 3/4/5 46/156 (29.5%) 36/161 (22.4%) 
All grades 156/156 (100%) 161/161 (100%) 
      
Acute and late 
period 
    
Grade 3/4/5 145/162 (89.5%) 146/165 (88.5%) 
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Supplementary Table 5B: Mean number of acute, late and overall toxicity events per patient, by Common Toxicity Criteria Adverse Events 
(CTCAE) version 4.0 grade method for each of the treatment arms, as per protocol analysis .  
  
Toxicity grouping 
Mean number of events per patient   
Cisplatin+RT Cetuximab+RT P value 
 Acute (T of TAME)       
Grade 3/4/5 (95% CI) 4.40 (3.85 to 4.95) 4.40 (3.88 to 4.91) 0.984 
All grades 19.96 (18.80 to 21.12) 20.47 (19.30 to 21.65) 0.541 
 Late (A of TAME)       
Grade 3/4/5 0.42 (0.30 to 0.55) 0.48 (0.29 to 0.66) 0.638 
All grades 9.59 (8.67 to 10.48) 9.96 (9.11 to 10.82) 0.543 
Overall        
Grade 3/4/5 4.79 (4.21 to 5.39) 4.86 (4.25 to 5.47) 0.891 
All grades 29.28 (27.45 to 31.12) 30.27 (28.46 to 32.08) 0.452 
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Supplementary table 5C: Toxicity outcomes for patients that have had complete regimen of treatment (3 doses for cisplatin 
and full 8 doses of cetuximab) 
 
Toxicity grouping 
Mean number of events per patient   
Cisplatin+RT 
N=62 
Cetuximab+RT 
N=130 
P value 
 Acute (T of TAME)       
Grade 3/4/5 (95% CI) 4.13 (3.31 to 4.95) 4.11 (3.54 to 4.69) 0.977 
Grade 3/4 (95% CI) 4.13 (3.31 to 4.95) 4.11 (3.54 to 4.69) 0.977 
All grades 19.16 (17.27 to 21.05) 19.75 (18.49 to 21.01) 0.604 
 Late (A of TAME)       
Grade 3/4/5 0.26 (0.08 to 0.44) 0.41 (0.20 to 0.63) 0.365 
All grades 9.08 (7.62 to 10.54) 9.46 (8.54 to 10.38) 0.654 
Overall        
Grade 3/4/5 4.39 (3.49 to 5.28) 4.53 (3.85 to 5.21) 0.812 
All grades 28.06 (25.09 to 31.04) 29.05 (27.13 to 30.96) 0.573 
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Supplementary table S6: relatedness of serious adverse events  
 
Chi-squared test to compare groups, SAE= serious adverse events 
 
Could this event have 
been caused by the trial 
medication? 
Definitely related to trial 
medication 
Cisplatin+RT Cetuximab+RT Total 
42 (25.9%) 4 (4.2%) 46 (17.9%) 
Probably related to trial 
medication 
56 (34.6%) 14 (14.7%) 70 (27.2%) 
Possibly related to trial 
medication 
37 (22.8%) 34 (35.8%) 71 (27.6%) 
Unlikely to be relate to 
trial medication 
14 (8.6%) 21 (22.1%) 35 (13.6%) 
Unrelated to trial 
medication 
12 (7.4%) 22 (23.2%) 34 (13.2%) 
Missing 1 (0.6%)  - 1 (0.4%) 
Total 162 95 
(P-value for trend  
<0.0001) 
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Supplementary Table S7: Causes of serious adverse events, by treatment group. 
In alphabetical order of SAE event type 
SAE Event 
Cisplatin+RT Cetuximab+RT Total 
Mean 
events 
Proportion of 
patients (%) 
Mean 
events 
Proportion of 
patients (%) 
Mean 
events 
Proportion of 
patients (%) 
Gastrointestinal disorders | Abdominal pain 0.02 2/162 (1.2%) 0.01 1/165 (0.6%) 0.01 3/327 (0.9%) 
Renal and urinary disorders | Acute kidney injury 0.14 16/162 (9.9%) - - 0.07 16/327 (4.9%) 
Gastrointestinal disorders | Anal ulcer 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Blood and lymphatic system disorders | Anemia 0.02 3/162 (1.9%) - - 0.01 3/327 (0.9%) 
Metabolism and nutrition disorders | Anorexia 0.15 16/162 (9.9%) 0.09 13/165 (7.9%) 0.12 29/327 (8.9%) 
Respiratory, thoracic and mediastinal disorders | 
Aspiration 0.01 1/162 (0.6%) 0.02 3/165 (1.8%) 0.01 4/327 (1.2%) 
Respiratory, thoracic and mediastinal disorders | 
Atelectasis 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Cardiac disorders | Atrial fibrillation - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Blood and lymphatic system disorders | Blood 
and lymphatic system disorders - Other, specify 0.02 4/162 (2.5%) - - 0.01 4/327 (1.2%) 
Cardiac disorders | Cardiac disorders - Other, 
specify - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Infections and infestations | Catheter related 
infection - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Gastrointestinal disorders | Colitis - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Gastrointestinal disorders | Colonic perforation - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Psychiatric disorders | Confusion 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Gastrointestinal disorders | Constipation 0.12 16/162 (9.9%) 0.04 6/165 (3.6%) 0.08 22/327 (6.7%) 
Respiratory, thoracic and mediastinal disorders | 
Cough 0.01 2/162 (1.2%) 0.01 1/165 (0.6%) 0.01 3/327 (0.9%) 
Investigations | Creatinine increased 0.02 4/162 (2.5%) - - 0.01 4/327 (1.2%) 
Metabolism and nutrition disorders | 
Dehydration 0.21 26/162 (16%) 0.13 16/165 (9.7%) 0.17 42/327 (12.8%) 
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Injury, poisoning and procedural complications | 
Dermatitis radiation - - 0.04 6/165 (3.6%) 0.02 6/327 (1.8%) 
Infections and infestations | Device related 
infection 0.01 1/162 (0.6%) 0.02 3/165 (1.8%) 0.01 4/327 (1.2%) 
Gastrointestinal disorders | Diarrhea 0.04 7/162 (4.3%) 0.02 2/165 (1.2%) 0.03 9/327 (2.8%) 
Gastrointestinal disorders | Dry mouth - - 0.01 1/165 (0.6%) 0.01 1/327 (0.3%) 
Gastrointestinal disorders | Dyspepsia 0.02 2/162 (1.2%) - - 0.01 2/327 (0.6%) 
Gastrointestinal disorders | Dysphagia 0.10 13/162 (8%) 0.08 10/165 (6.1%) 0.09 23/327 (7%) 
Respiratory, thoracic and mediastinal disorders | 
Dyspnea 0.02 4/162 (2.5%) 0.01 1/165 (0.6%) 0.02 5/327 (1.5%) 
General disorders and administration site 
conditions | Edema limbs 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Gastrointestinal disorders | Esophageal pain 0.01 2/162 (1.2%) - - 0.01 2/327 (0.6%) 
General disorders and administration site 
conditions | Fatigue 0.02 3/162 (1.9%) 0.02 3/165 (1.8%) 0.02 6/327 (1.8%) 
Blood and lymphatic system disorders | Febrile 
neutropenia 0.04 6/162 (3.7%) - - 0.02 6/327 (1.8%) 
General disorders and administration site 
conditions | Fever 0.08 12/162 (7.4%) 0.04 6/165 (3.6%) 0.06 18/327 (5.5%) 
Musculoskeletal and connective tissue disorders 
| Flank pain 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
General disorders and administration site 
conditions | Flu like symptoms 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Gastrointestinal disorders | Gastric hemorrhage - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Gastrointestinal disorders | Gastroesophageal 
reflux disease - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Gastrointestinal disorders | Gastrointestinal 
disorders - Other, specify 0.01 1/162 (0.6%) 0.02 4/165 (2.4%) 0.02 5/327 (1.5%) 
Gastrointestinal disorders | Gastrointestinal pain 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Respiratory, thoracic and mediastinal disorders | 
Hoarseness - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Metabolism and nutrition disorders | 
Hypercalcemia 0.01 1/162 (0.6%) 0.01 1/165 (0.6%) 0.01 2/327 (0.6%) 
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Metabolism and nutrition disorders | 
Hyperkalemia 0.01 2/162 (1.2%) 0.01 1/165 (0.6%) 0.01 3/327 (0.9%) 
Metabolism and nutrition disorders | 
Hypernatremia 0.01 1/162 (0.6%) 0.01 1/165 (0.6%) 0.01 2/327 (0.6%) 
Metabolism and nutrition disorders | 
Hypokalemia 0.04 5/162 (3.1%) 0.02 3/165 (1.8%) 0.03 8/327 (2.4%) 
Metabolism and nutrition disorders | 
Hypomagnesemia 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Metabolism and nutrition disorders | 
Hyponatremia 0.01 1/162 (0.6%) - - 0.01 1/327 (0.3%) 
Metabolism and nutrition disorders | 
Hypophosphatemia 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Vascular disorders | Hypotension - - 0.02 4/165 (2.4%) 0.01 4/327 (1.2%) 
Respiratory, thoracic and mediastinal disorders | 
Hypoxia 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Infections and infestations | Infections and 
infestations - Other, specify 0.05 7/162 (4.3%) 0.02 4/165 (2.4%) 0.04 11/327 (3.4%) 
Injury, poisoning and procedural complications | 
Injury, poisoning and procedural complications - 
Other, specify - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Investigations | Investigations - Other, specify 0.03 4/162 (2.5%) - - 0.02 4/327 (1.2%) 
Respiratory, thoracic and mediastinal disorders | 
Laryngeal mucositis 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Cardiac disorders | Left ventricular systolic 
dysfunction 0.01 2/162 (1.2%) - - 0.01 2/327 (0.6%) 
Nervous system disorders | Lethargy 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Infections and infestations | Lung infection 0.01 1/162 (0.6%) 0.02 2/165 (1.2%) 0.02 3/327 (0.9%) 
Metabolism and nutrition disorders | Metabolism 
and nutrition disorders - Other, specify 0.02 1/162 (0.6%) 0.01 1/165 (0.6%) 0.01 2/327 (0.6%) 
Infections and infestations | Mucosal infection 0.01 1/162 (0.6%) 0.01 1/165 (0.6%) 0.01 2/327 (0.6%) 
Gastrointestinal disorders | Mucositis oral 0.17 
25/162 
(15.4%) 0.17 21/165 (12.7%) 0.17 46/327 (14.1%) 
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Musculoskeletal and connective tissue disorders 
| Muscle weakness left-sided - - 0.01 1/165 (0.6%) 0.01 1/327 (0.3%) 
Cardiac disorders | Myocardial infarction 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Gastrointestinal disorders | Nausea 0.41 
46/162 
(28.4%) 0.12 16/165 (9.7%) 0.26 62/327 (19%) 
Neoplasms benign, malignant and unspecified 
(incl cysts and polyps) | Neoplasms benign, 
malignant and unspecified (incl cysts and polyps) 
- Other, specify - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Investigations | Neutrophil count decreased 0.02 3/162 (1.9%) - - 0.01 3/327 (0.9%) 
General disorders and administration site 
conditions | Non-cardiac chest pain 0.01 1/162 (0.6%) - - 0.01 1/327 (0.3%) 
Gastrointestinal disorders | Oral hemorrhage 0.01 2/162 (1.2%) 0.01 1/165 (0.6%) 0.01 3/327 (0.9%) 
Gastrointestinal disorders | Oral pain 0.04 4/162 (2.5%) 0.07 6/165 (3.6%) 0.05 10/327 (3.1%) 
General disorders and administration site 
conditions | Pain - - 0.01 1/165 (0.6%) 0.01 1/327 (0.3%) 
Musculoskeletal and connective tissue disorders 
| Pain in extremity 0.01 1/162 (0.6%) 0.01 1/165 (0.6%) 0.01 2/327 (0.6%) 
Nervous system disorders | Paresthesia - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Cardiac disorders | Pericarditis 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Vascular disorders | Peripheral ischemia 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Respiratory, thoracic and mediastinal disorders | 
Pharyngeal hemorrhage - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Respiratory, thoracic and mediastinal disorders | 
Pharyngeal mucositis 0.02 4/162 (2.5%) 0.02 3/165 (1.8%) 0.02 7/327 (2.1%) 
Investigations | Platelet count decreased 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Respiratory, thoracic and mediastinal disorders | 
Pneumonitis 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Respiratory, thoracic and mediastinal disorders | 
Productive cough 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Skin and subcutaneous tissue disorders | Pruritus - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Skin and subcutaneous tissue disorders | Rash 
acneiform - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
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Renal and urinary disorders | Renal and urinary 
disorders - Other, specify 0.02 2/162 (1.2%) - - 0.01 2/327 (0.6%) 
Respiratory, thoracic and mediastinal disorders | 
Respiratory, thoracic and mediastinal disorders - 
Other, specify 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Infections and infestations | Salivary gland 
infection 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Infections and infestations | Sepsis 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Investigations | Serum amylase increased 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Cardiac disorders | Sinus tachycardia 0.02 2/162 (1.2%) - - 0.01 2/327 (0.6%) 
Infections and infestations | Skin infection 0.01 1/162 (0.6%) 0.02 4/165 (2.4%) 0.02 5/327 (1.5%) 
Skin and subcutaneous tissue disorders | Skin 
ulceration - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Respiratory, thoracic and mediastinal disorders | 
Sore throat 0.04 5/162 (3.1%) 0.02 3/165 (1.8%) 0.03 8/327 (2.4%) 
Infections and infestations | Stoma site infection 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Gastrointestinal disorders | Stomach pain 0.02 1/162 (0.6%) - - 0.01 1/327 (0.3%) 
General disorders and administration site 
conditions | Sudden death NOS - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Nervous system disorders | Syncope 0.01 2/162 (1.2%) 0.01 2/165 (1.2%) 0.01 4/327 (1.2%) 
Vascular disorders | Thromboembolic event 0.01 2/162 (1.2%) 0.01 1/165 (0.6%) 0.01 3/327 (0.9%) 
Infections and infestations | Upper respiratory 
infection 0.01 2/162 (1.2%) 0.01 1/165 (0.6%) 0.01 3/327 (0.9%) 
Renal and urinary disorders | Urinary retention 0.01 1/162 (0.6%) - - 0.00 1/327 (0.3%) 
Infections and infestations | Urinary tract 
infection 0.01 2/162 (1.2%) - - 0.01 2/327 (0.6%) 
Ear and labyrinth disorders | Vertigo - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Ear and labyrinth disorders | Vestibular disorder - - 0.01 1/165 (0.6%) 0.00 1/327 (0.3%) 
Gastrointestinal disorders | Vomiting 0.43 
48/162 
(29.6%) 0.17 22/165 (13.3%) 0.30 70/327 (21.4%) 
Investigations | Weight loss 0.06 7/162 (4.3%) 0.03 5/165 (3%) 0.04 12/327 (3.7%) 
Infections and infestations | Wound infection 0.01 2/162 (1.2%) - - 0.01 2/327 (0.6%) 
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Supplementary Figure S1A: Acute, late and overall (combined) toxicities, by severity and treatment group.  
Severe toxicity classified as grade 3,4 or5, assessed using the Common Toxicity Criteria Adverse Events (CTCAE) version 4. All grades=CTCAE 
grades 0-5. A toxicity that reaches grade 3-5 in the acute phase and continues as Grade 3-5 into the late phase is counted as both an acute and a 
late severe toxicity, but only counted once in overall severe toxicity.
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Supplementary Figure S1B: Serious adverse events by severity , by group  
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Supplementary Figure S2:  Proportion of patients with persistent disease, loco-regional recurrence, distant metastases and second primaries, 
by treatment group. Some patients treated with cetuximab had both loco-regional recurrence and distant metastasis synchronously and are 
included in a separate grouping. 
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Supplementary Figure S3:  Recurrences and post-hoc subgroup analyses  
A. Overall survival of patients with TNM8 stage I and II disease (excludes patients with T4 and N3) n=276 
 
The 2-year survival rate with 95% confidence interval is:  
-          98.4% (93.9% to 99.6%) in the cisplatin arm 
-          93.2% (87.4% to 96.4%) in the cetuximab arm 
Hazards Ratio: 4.27, 95% CI: 0.92 to 19.75; Log rank p-value = 0.043 
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B. Overall survival for patients with T4 or N3 disease, by trial group. N=58. 
 The 2-year survival rate with 95% confidence interval is 93.3% (75.9% to 98.3%) in the Cisplatin and Radiotherapy arm and 67.1% (42.5% 
to 83.1%) in the Cetuximab and Radiotherapy arm.   Log-rank p-value= 0.03; HR: 4.83, 95% CI: 1.00 to 23.31 
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C. Overall survival of patients with doubly-positive on p16 immunohostochemistry and High-Risk HPV DNA in-situ hybridization, n=304 
The 2-year survival rate with 95% confidence interval is:  
-          97.2% (92.8% to 99%) in the cisplatin arm 
-          89.7% (83.2% to 93.8%) in the cetuximab arm          Hazards Ratio 4.4, 95% CI: 1.49 to 13.11        Log rank p-value = 0.004 
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D. Kaplan-Meier curve for overall survival in per-protocol analysis . 
2 year OS rate for Cisplatin: 97.5%, 95% CI: 93.4% to 99.1%; 2 year OS rate for Cetuximab: 90.0%, 95% CI: 83.8% to 93.8%, HR: 4.76, 95% 
CI: 1.61 to 14.05, log-rank p-value=0.0019 
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Supplementary Figure S4:  Quality of life measured by EORTC C30 questionnaire and swallowing measured by the MD Anderson Dysphagia 
Questionnaire (MDADI)  
 
A. EORTC Physical functioning 
P-value = 0.122 
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B. EORTC Role functioning 
P-value = 0.121 
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C. EORTC Emotional functioning 
P-value = 0.851 
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D. EORTC Cognitive functioning 
P-value = 0.443 
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E. EORTC Social functioning  
P-value = 0.182 
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F. MDADI dysphagia global  
P-value = 0.0948 
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G. MDADI dysphagia emotional 
P-value = 0.088 
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H. MDADI dysphagia functional 
P-value = 0.026 
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I. MDADI dysphagia physical 
P-value = 0.079 
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J. MDADI dysphagia overall function  
P-value = 0.042 
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Data sharing statement: 
Deidentified participant data, and  data dictionary  will be available along with  study protocol and  statistical analysis plan; from 01 
Jan 2020 onwards. Please write to M.L.Dalby@warwick.ac.uk 
1. The final dataset will include basic demographics, tumour characteristics, treatment detail, survival and quality of life and toxicity 
outcomes.  Data will not include name, address, hospital number or date of birth, or any other identifying data. 
 
2. The data will be accompanied by metadata which gives a complete explanation of the data fields, the definition, the standards used such 
as TNM staging, and the units used. 
 
3. The data will be shared through custodianship by the principle investigator.  A data access committee will be convened and will comprise 
of the principle investigator and two other co investigators.  They will be responsible for assessing requests for data sharing on granting access. 
The data management committee will be responsible to the steering committee and requests for appeals will be made directly to the Trial Steering 
Committee. 
 
4. The process for requesting data sharing will be as follows: 
• The requestor will complete a two page proforma requiring name and contact details of requestor, the objectives of the study, the 
methodology, the expected outcome, the statistical analysis plan, whether the project will be a collaboration with the DeESCALaTE study 
organisers or will only acknowledge the study and its organisers, ethical committee approval, funding and peer review details.  The data 
sharing committee will meet at least twice a year to consider these requests.  Urgent requests may be considered in between these 
meetings. 
• In the event of a declined application, the requestors may lodge an appeal with the trial Steering Committee Chairperson. 
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5. The dataset will be stored with the principle investigator at the Institute of Head and Neck Studies and Education in the long-term.  The 
data will be available for public release from the time of publication of the main results of the study.  Prior to that access of the data may be 
considered in specific circumstances.  After five years of publication of the result, the data may then be lodged with a data archiving facility.   
 
6. Requestors who are granted access to the data will be required to complete a data sharing agreement which is based upon the principles, 
content and format published by the NCRI at http://www.ncri.or.uk/default.asp?s=1&p=8&ss=9 
 
 
 
